Maze officer may sell stock for tax withholding

An officer of Maze Therapeutics filed a Rule 144 notice reflecting issuer-mandated sales tied to RSU vesting and recent 7,500-share transactions.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) has a notice of proposed sale of common stock filed on behalf of officer Atul Dandekar under Rule 144. The stock relates to restricted stock units that vested as compensation, and the company mandated a sale of shares to cover tax withholding obligations tied to that vesting.

The notice also lists recent sales by Dandekar over the prior three months, each for 7,500 shares of Maze common stock, with aggregate proceeds a little above $200,000 per transaction.

Key Figures

Shares sold June 29, 2026: 7,500 shares Proceeds June 29, 2026: $210,150.00 Shares sold July 29, 2026: 7,500 shares +3 more

6 metrics

Shares sold June 29, 2026 7,500 shares Securities sold during the past 3 months by the officer

Proceeds June 29, 2026 $210,150.00 Aggregate proceeds for 7,500 shares sold June 29, 2026

Shares sold July 29, 2026 7,500 shares Securities sold during the past 3 months by the officer

Proceeds July 29, 2026 $205,031.44 Aggregate proceeds for 7,500 shares sold July 29, 2026

Shares sold August 28, 2026 7,500 shares Securities sold during the past 3 months by the officer

Proceeds August 28, 2026 $206,823.75 Aggregate proceeds for 7,500 shares sold August 28, 2026

Key Terms

Rule 144, restricted stock units, tax withholding obligations, equity incentive award

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"vesting and settlement of restricted stock units granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"includes an amount necessary to satisfy tax withholding obligations"

equity incentive award financial

"units granted pursuant to an equity incentive award"

Equity incentive award is a grant of company ownership or the right to buy ownership—such as stock, restricted shares, or options—given to employees, executives, or directors as part of their pay. Investors care because these awards align workers’ interests with shareholders (like giving someone slices of a pie so they try to make the pie bigger), but they also dilute existing ownership and increase reported compensation costs, which can affect share value and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for MAZE?

It reports that officer Atul Dandekar may sell Maze Therapeutics common stock under Rule 144. The shares relate to restricted stock units that vested as compensation, and the issuer mandated a sale sufficient to satisfy related tax withholding obligations.

Who is selling Maze Therapeutics (MAZE) stock in this Form 144?

The notice is filed for Atul Dandekar, identified as an officer of Maze Therapeutics, Inc. It covers Maze common stock held for his account, including shares from restricted stock unit vesting under an equity incentive award.

How many MAZE shares did the officer sell recently?

Over the past three months, the officer reported three sales of 7,500 shares each of Maze common stock, dated June 29, 2026, July 29, 2026, and August 28, 2026, as part of the historical sales section in the notice.

What dollar amounts were involved in the recent MAZE stock sales?

The three reported sales produced aggregate proceeds of $210,150.00 on June 29, 2026, $205,031.44 on July 29, 2026, and $206,823.75 on August 28, 2026, for 7,500 shares in each transaction.

Why were some MAZE shares sold according to this notice?

The remarks state that the reported sale was mandated by the issuer and includes shares sold to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units granted under an equity incentive award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 07:03 PM EDT Accepted by SEC EDGAR 09/02/2026 - 07:03 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002050167
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MAZE THERAPEUTICS, INC.
SEC File Number	001-42490
Address of Issuer	171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	650-850-5070
Name of Person for Whose Account the Securities are To Be Sold	Atul Dandekar
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza, 8th Floor New York NY 10004	6679	177200	55549168	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/01/2026	Restricted Stock Unit Vesting	Issuer			6679	09/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Atul Dandekar c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	06/29/2026	7500	210150.00
Atul Dandekar c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	07/29/2026	7500	205031.44
Atul Dandekar c/o Maze Therapeutics, Inc. 171 Oyster Point Boulevard, Suite 300 South San Francisco CA 94080	Common Stock	08/28/2026	7500	206823.75

144: Remarks and Signature

Remarks	The reported sale was mandated by the Issuer and includes an amount necessary to satisfy tax withholding obligations resulting from the vesting and settlement of restricted stock units granted pursuant to an equity incentive award.
Date of Notice	09/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Atul Dandekar
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)